Cytokinetics Inc (NAS:CYTK)
$ 48.98 -10.25 (-17.31%) Market Cap: 5.14 Bil Enterprise Value: 6.35 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Q4 2021 Cytokinetics Inc Earnings Call Transcript

Feb 24, 2022 / 09:30PM GMT
Release Date Price: $33.95 (+8.29%)
Operator

Good afternoon and welcome, ladies and gentlemen, to Cytokinetics' fourth quarter 2021 conference call. (Operator Instructions). I will now turn the call over to Joanna Siegall, Cytokinetics' Senior Manager of Corporate Communications and Investor Relations. Please go ahead.

Joanna Siegall
Cytokinetics, Incorporated - Senior Manager, Corporate Communications & IR

Thanks. Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with a brief overview of the quarter and recent developments. Fady Malik, EVP of R&D, will then provide updates related to omecamtiv mecarbil and CK-136. Stuart Kupfer, SVP and Chief Medical Officer will provide an update on aficamten and reldesemtiv. Andrew Callos, EVP and Chief Commercial Officer, will discuss commercialization planning activities for omecamtiv mecarbil. Robert Wong, VP and Chief Accounting Officer, will provide a financial overview for the past quarter. And Ching Jaw, SVP and Chief Financial Officer, will discuss our 2022 financial guidance and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot